Home / Stocks / Aarey Drugs & Pharm Ltd
AAREYDRUGS

Aarey Drugs & Pharm Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹112.2

Change

+4.45 (4.13%)

Open

₹108.97

Prev. Close

₹107.75

Day High

₹113.13

Day Low

₹106.36

Volume Analysis

Traded

264,554

Delivered

207,736

Delivery %

78.52%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (3)

  • •Promoter holding is falling
  • •Below-average fundamentals quality score (43/100)
  • •Low operating margin (1.5%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹121.53 ₹117.33 ₹114.76 ₹110.56 ₹107.99 ₹103.79 ₹101.22
Fibonacci ₹117.33 ₹114.74 ₹113.15 ₹110.56 ₹107.97 ₹106.38 ₹103.79
Camarilla ₹114.06 ₹113.44 ₹112.82 ₹110.56 ₹111.58 ₹110.96 ₹110.34

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+66.1%

1 Week

-1.67%

1 Month

+0.24%

3 Months

+38.18%

6 Months

+33.99%

1 Year

+18.64%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

2.36%

Net margin 0.85% × asset turnover 1.5x × equity multiplier 1.85x

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Aarey Drugs & Pharm Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 43/100. The strongest factor is Financial Strength (98/100), while Growth (12/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling; below-average fundamentals quality score (43/100).

TopFund Score — Fundamentals Quality

43/100 — Weak

Data confidence: 74/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

98

Growth

12

Cash Flow

33

Corporate Governance

43

Institutional Ownership

44

Business Quality

36

Risk & Volatility

31

Liquidity

36

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Pursuant to Regulation 47 of SEBI (LODR) Regulation, 2015, the company has published and extract of statement of unaudited standalone Financial ....

Aarey Drugs reports no deviation in warrant proceeds; ₹2,481.82 lakh received, ₹900 lakh unutilised as of 30 Sep 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026 (S)
Sales + 58 76 210 127 105 134 108 102 84 96 189 45 89
Expenses + 56 74 212 126 101 132 112 101 82 98 185 43 86
Operating Profit 2 3 -1 1 4 2 -4 2 3 -2 4 1 2
OPM % 3.18% 3.53% -0.68% 0.93% 3.54% 1.64% -3.89% 1.67% 3.14% -1.57% 2.29% 2.96% 2.41%
Other Income + 1 0 5 2 0 1 8 2 1 4 0 2 2
Interest 0 0 0 1 0 1 1 1 1 1 2 2 1
Depreciation 1 1 1 0 2 1 0 0 1 1 1 1 1
Profit before tax 1 1 2 1 2 1 2 2 1 1 1 1 2
Tax % -22.0% 30.14% -0.47% 6.77% 8.62% 48.57% 71.6% 20.81% 31.08% 38.04% -21.88% -98.08% 17.47%
Net Profit + 1 1 2 1 2 1 0 1 1 1 2 1 1
EPS in Rs 0 0 1 0 1 0 0 0 0 0 1 0 0
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -24 22 29 149 82 75 -49 -19 -20 -28 75 -56 5

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Sales + 213 246 396 349 354 298 348 493 419 396 474 472
Expenses + 212 245 386 342 347 294 344 481 411 391 471 465
Operating Profit 1 1 10 8 8 3 5 11 8 4 3 7
OPM % 0.6% 0.4% 2.4% 2.2% 2.2% 1.1% 1.3% 2.3% 1.8% 1.1% 0.6% 1.5%
Other Income + 3 3 3 3 4 7 7 3 3 7 10 6
Interest 1 2 4 2 2 2 2 2 3 4 5 5
Depreciation 1 1 1 1 1 1 1 2 2 2 2 3
Profit before tax 1 2 8 8 9 7 8 10 6 5 6 5
Tax % 23.0% 29.0% 31.0% 25.0% 27.0% 20.0% 21.0% 35.0% 37.0% 12.0% 34.0% 27.0%
Net Profit + 1 1 5 6 7 6 7 7 4 5 4 4
EPS in Rs 1 1 3 3 3 2 3 3 1 2 1 1
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 4.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sales growth 7 15 61 -12 1 -16 17 41 -15 -6 20 0

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S) Sep 2026 (S)
Reserves 19 20 31 57 63 69 75 88 92 105 110 122 138
Borrowings + 11 15 10 3 16 18 18 14 38 31 35 50 56
Other Liabilities + 69 74 83 86 43 84 116 117 136 139 117 97 89
Total Liabilities 115 125 142 170 146 194 233 245 291 303 291 297 315
Fixed Assets + 6 8 12 12 12 12 14 14 14 13 16 18 21
CWIP 0 0 0 0 0 0 0 0 0 0 0 8 2
Investments 0 0 0 0 0 0 0 0 0 1 2 2 2
Other Assets + 109 117 130 157 133 181 218 230 277 289 272 269 289
Total Assets 115 125 142 170 146 194 233 245 291 303 291 297 315
Equity Capital 17 17 18 23 23 23 23 25 25 28 28 28 32

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Cash from Operating Activity + 3 6 1 -20 1 3 5 0 -1 -3 10 10
Cash from Investing Activity + -2 -3 -5 -1 -1 -1 -3 -3 0 -2 -6 -12
Cash from Financing Activity + -2 -2 4 23 -2 -2 -2 2 1 6 -4 2
Net Cash Flow -1 1 -1 2 -3 0 0 0 1 1 0 0
Free Cash Flow 1 3 -4 -21 -1 2 3 -2 -2 -4 5 -2
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 239 560 28 -232 37 135 154 36 13 -37 421 164

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 50.04% → 41.46%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 46.12% 51.31% 51.32% 51.81% 52.86% 52.86% 53.23% 54.07% 57.09% 56.49% 55.87% 52.83%
Promoters 50.04% 45.28% 45.28% 45.44% 44.8% 44.8% 44.8% 44.8% 39.05% 37.71% 37.71% 41.46%
FII 3.83% 3.4% 3.4% 2.75% 2.34% 2.34% 1.97% 1.13% 3.86% 4.18% 4.81% 4.28%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.62% 1.62% 1.44%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Aarey Drugs & Pharm Ltd (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Aarey Drugs & Pharm Ltd?

Frequently Asked Questions about Aarey Drugs & Pharm Ltd

Community Sentiment

What are other investors saying about Aarey Drugs & Pharm Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.